If you follow weight loss drug news even casually — and at this point, who does not — you probably saw the headlines this week: Novo Nordisk has dropped its patent infringement case against compounded versions of semaglutide. Shares of compounding pharmacy companies surged. Social media exploded with celebration.
And in my group chat with three friends who have been on or considering GLP-1 medications, the reaction was immediate: "Does this mean we can finally get it cheaper?"
Maybe. But as someone who has spent the last six months researching these drugs obsessively (I started when my doctor suggested I consider Wegovy for my own weight management), I think the celebration is running ahead of some important questions that nobody seems to want to ask.
Important disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications like semaglutide are prescription drugs with real risks and side effects. Always consult your doctor or a qualified healthcare provider before starting, stopping, or switching any medication. Do not use compounded medications without medical supervision.
What Actually Happened (And What It Means)
Novo Nordisk, the Danish pharmaceutical company that makes Wegovy (semaglutide for weight loss) and Ozempic (semaglutide for type 2 diabetes), had been suing compounding pharmacies that produce their own versions of semaglutide. These compounded versions are significantly cheaper — often $200-400 per month compared to Wegovy's list price of roughly $1,350 per month.
The company's decision to drop these lawsuits is a major shift. The practical effect is that compounding pharmacies can continue producing semaglutide without the immediate threat of legal action. Companies like Hims & Hers, which have built significant businesses around compounded GLP-1 drugs, saw their stock prices jump on the news.
For the estimated 40+ million American adults who could benefit from GLP-1 medications but cannot afford the brand-name versions, this sounds like unambiguously good news. And in some ways, it is.
But here is where it gets complicated.
Compounded Semaglutide Is NOT Generic Semaglutide
This distinction matters enormously, and I am not seeing it explained clearly in most coverage.
A generic drug goes through FDA approval. It must demonstrate bioequivalence to the brand-name drug — meaning it delivers the same amount of active ingredient to the bloodstream in the same timeframe. Generic drugs are manufactured in FDA-inspected facilities under strict quality controls.
A compounded drug is mixed by a compounding pharmacy, often to create a specific dose or formulation. Compounded drugs are NOT FDA-approved. They do not go through the same rigorous testing process. The FDA itself states that compounded drugs "are not FDA-approved" and that the agency "generally cannot assure their safety, effectiveness, or quality."
This does not automatically mean compounded semaglutide is dangerous. Many compounding pharmacies are reputable, use quality ingredients, and produce reliable products. But the regulatory framework is fundamentally different, and that matters.
My friend Kesha, a pharmacist who has been fielding questions about this nonstop, put it this way: "It is the difference between buying a car from a dealership with inspections and warranties, and buying one from a guy in a parking lot who says it runs great. The parking lot car might be perfectly fine. But you are taking on more risk, and if something goes wrong, you have less recourse."
What the FDA Actually Says
The FDA has been explicit about its concerns regarding compounded semaglutide. In December 2023, the agency issued a safety alert warning consumers about potential risks, including:
- Dosing inconsistency: Compounded versions may not contain the exact amount of semaglutide claimed, leading to under- or over-dosing
- Purity concerns: Without FDA manufacturing oversight, there is a higher risk of contamination or degradation
- Salt form differences: Some compounding pharmacies use semaglutide sodium salt instead of the semaglutide base used in Wegovy. These are chemically different and may not behave identically in the body
- Sterility issues: Injectable medications require sterile manufacturing. Compounding pharmacies operate under different sterility standards than large pharmaceutical manufacturers
In 2024 and 2025, the FDA reported adverse events associated with compounded semaglutide products, including hospitalizations. The agency urged consumers to use only FDA-approved versions when available.
Now, I want to be fair here. Novo Nordisk has a massive financial incentive to discourage people from using cheaper alternatives. The FDA, while independent, has faced criticism from patient advocacy groups for what some perceive as regulatory capture by major pharmaceutical companies. These are legitimate criticisms.
But the safety concerns are also legitimate. You are injecting a substance into your body. The manufacturing quality matters.
The Cost Reality
Let me be honest about why people are turning to compounded versions: brand-name GLP-1 drugs are absurdly expensive, and insurance coverage is a mess.
- Wegovy list price: ~$1,350/month
- With insurance (if covered): $0-500/month (highly variable)
- Without insurance: $1,000-1,350/month
- Compounded semaglutide: $200-400/month
According to a KFF survey, only about 25% of adults with health insurance have coverage for weight loss medications. Medicare explicitly does not cover drugs prescribed for weight loss (though legislation to change this has been introduced). Medicaid coverage varies by state.
So for the majority of people who could benefit from these drugs, the choice is: pay over $1,000 per month for the FDA-approved version, or pay $200-400 for a compounded version that may or may not be equivalent. When you frame it that way, is it really surprising that millions of people are choosing the cheaper option?
My sister-in-law, who makes $52,000 a year and has no weight loss medication coverage on her insurance, looked at me like I was insane when I mentioned the branded price. "That is my car payment, my phone bill, and my groceries combined," she said. "For one drug. Every month."
How to Be Smart About This
If you are considering compounded semaglutide — and I understand why you might be — here is how to minimize your risk, based on conversations with pharmacists, endocrinologists, and the FDA's own guidance.
1. Only Use a Licensed Compounding Pharmacy
Check that the pharmacy is licensed in your state and preferably accredited by the Pharmacy Compounding Accreditation Board (PCAB). Section 503B outsourcing facilities are held to higher manufacturing standards than traditional 503A compounding pharmacies. If you can find a 503B facility, that is your better option.
2. Get a Real Prescription
Do not buy semaglutide from a website that does not require a prescription from a licensed physician. If someone is selling you injectable medication without a doctor's involvement, run. This is non-negotiable.
3. Start Low, Go Slow
One advantage of the brand-name drugs is their carefully titrated dosing schedule — you start at a low dose and gradually increase over weeks. If you are using a compounded version, make sure your doctor is following a similar titration protocol. The side effects of semaglutide (nausea, vomiting, diarrhea, constipation) are dose-dependent. Going too high too fast is miserable and potentially dangerous.
4. Monitor Yourself
Report any unusual side effects to your doctor immediately. Keep a log of your injections, doses, and how you feel. If you experience severe nausea, pancreatitis symptoms (severe abdominal pain radiating to the back), or allergic reactions, seek medical attention immediately.
5. Know That You Might Be Getting a Different Product
Ask the compounding pharmacy specifically what form of semaglutide they use. Semaglutide base and semaglutide sodium are not interchangeable at the same dose. If they cannot tell you, or if they do not seem to understand the question, find a different pharmacy.
The Bigger Question Nobody Is Asking
The real scandal here is not that compounding pharmacies are making cheaper semaglutide. It is that a drug this effective costs $1,350 per month in the first place.
According to a Yale study, the estimated cost to manufacture a month's supply of semaglutide is approximately $5. Five dollars. The rest is R&D recoupment, marketing, and profit. Novo Nordisk reported revenues of $36 billion in 2025, with GLP-1 drugs accounting for the majority.
I am not anti-pharma. Drug development is expensive and risky, and companies deserve to recoup their investments. But a 270x markup on a drug that treats a condition affecting 42% of American adults is difficult to justify on any moral framework I can think of.
Until the pricing issue is addressed — through generic competition, legislative action, or insurance reform — compounded versions will continue to exist because the market demands them. The question is not whether people will use cheaper alternatives. They already are. The question is how to make those alternatives as safe as possible.
Sources: U.S. Food and Drug Administration (fda.gov), Novo Nordisk press releases, KFF Health Tracking Survey, CDC National Health and Nutrition Examination Survey, Centers for Medicare & Medicaid Services, Yale School of Medicine cost analysis. This article is informational only — consult your healthcare provider before making any medication decisions.